FDA Approves Second Generic Abortion Pill Amid Rising Opposition

The FDA recently approved a second generic version of the abortion drug mifepristone, produced by Evita Solutions, aiming to increase accessibility and normalize abortion. This approval comes amid criticism from anti-abortion advocates who argue the drug is unsafe and causes harm to women and unborn children, with some accusing the FDA of approving it quietly just before a government shutdown. President Trump, who has pledged to leave abortion policy to the states, faces pressure from anti-abortion lawmakers to impose stricter federal restrictions on mifepristone. Public opposition exists against mail-order abortion pills without in-person doctor visits due to safety concerns, with some officials alleging the FDA has downplayed risks. Environmental and ethical concerns have also been raised about the chemical abortion pill's impact, including unmonitored medical waste polluting waterways. Despite promises of a review on chemical abortion pills, the FDA's approval of a new generic version has intensified debate over the safety, regulation, and ethics of medication abortions in the U.S.